Unlocking the power of molecular glues

Christian Ottmann, Luc Brunsveld, Michelle Arkin, Scott Clarke



Some of the most wanted therapeutic drug targets are still considered undruggable. The cutting edge research of Ambagon’s scientific founders has identified a way to solve this challenge through the use of “molecular glues” that stabilize native interactions of the 14-3-3 regulatory proteins. Ambagon’s technology has platform potential and is applicable in a variety of indications beyond cancer.

Christian Ottmann, co-founder & CTO: “Inkef recognized the potential of our technology based on strong scientific rationale, not on the hype”.

Unlocking the power of molecular glues | Inkef